Stemline Therapeutics Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.1M
Doctors Paid
7,655
Transactions
18,533
2024 Total
$4.6M
Payment Breakdown by Category
Research$17.2M (74.5%)
Consulting$2.2M (9.4%)
Food & Beverage$535,218 (2.3%)
Travel$486,098 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.2M | 1,366 | 74.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 708 | 10.2% |
| Consulting Fee | $2.2M | 467 | 9.4% |
| Food and Beverage | $535,218 | 14,539 | 2.3% |
| Travel and Lodging | $486,098 | 1,120 | 2.1% |
| Honoraria | $230,771 | 154 | 1.0% |
| Grant | $74,783 | 1 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $15,400 | 4 | 0.1% |
| Education | $2,724 | 173 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 1 | 0.0% |
Payments by Type
Research
$17.2M
1,366 transactions
General
$5.9M
17,167 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| STML-401-0314 | $3.1M | 0 | 191 |
| STML-401-0114 | $2.4M | 0 | 80 |
| EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | $2.3M | 0 | 678 |
| Tagraxofusp (SL-401) in Patients With CMML or MF | $1.7M | 0 | 105 |
| STML-IST-QLHC | $1.7M | 0 | 4 |
| Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | $1.3M | 0 | 9 |
| STML-IST-LAMB | $1.1M | 0 | 5 |
| Dana Farber Cancer Institute | $895,382 | 0 | 4 |
| STML-801-0115 | $645,325 | 0 | 116 |
| 401-IST-LANE | $378,422 | 0 | 3 |
| DANA FARBER CANCER INSTITUTE | $301,054 | 0 | 1 |
| A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer, Interventional | $239,929 | 3 | 42 |
| STML-701-0114 | $201,486 | 0 | 32 |
| STML-IST-AMB | $170,532 | 0 | 6 |
| STML-IST-PEM | $150,819 | 0 | 3 |
| STML-IST-SHOR | $120,000 | 0 | 2 |
| STML-401-0214 | $99,724 | 0 | 19 |
| STML-401-0414 | $89,808 | 0 | 7 |
| MD ANDERSON | $82,298 | 0 | 2 |
| STML-IST-GMB | $60,870 | 0 | 1 |
| STML-IST-BASH | $45,548 | 0 | 3 |
| STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | $5,436 | 11 | 41 |
| STML-901-0119 | $1,824 | 0 | 1 |
| A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | $953.32 | 0 | 8 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Serge Alexanian, M.d, M.D | Anatomic Pathology & Clinical Pathology | Los Angeles, CA | $749,467 | $0 |
| Enrique Garcia, Md, MD | Internal Medicine | Scarsdale, NY | $407,275 | $0 |
| Dr. Samir Khleif, M.d, M.D | Specialist | Augusta, GA | $205,500 | $0 |
| Anne O'dea, M.d, M.D | Medical Oncology | Westwood, KS | $190,238 | $0 |
| Dr. John Sloan, M.d, M.D | Internal Medicine | Boston, MA | $181,926 | $0 |
| Dr. Alejandro Gru, Md, MD | Dermatopathology | New York, NY | $144,345 | $0 |
| Dr. Fengting Yan, Md, Phd, MD, PHD | Internal Medicine | Seattle, WA | $125,232 | $0 |
| Sheeja Pullarkat, Md, MD | Anatomic Pathology | Los Angeles, CA | $113,851 | $0 |
| Dr. James Mccloskey, M.d, M.D | Hematology | Hackensack, NJ | $108,435 | $0 |
| Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD | Hematology & Oncology | Seattle, WA | $105,821 | $0 |
| Brian Poligone, Md, MD | Dermatology | Fairport, NY | $93,561 | $0 |
| Dr. Tariq Mughal, M.d, M.D | Hematology & Oncology | Worcester, MA | $87,934 | $0 |
| Dr. Rena Callahan, M.d, M.D | Hematology | Valencia, CA | $83,626 | $0 |
| Salman Fazal, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $83,592 | $0 |
| Ricardo Alvarez, Md, MD | Medical Oncology | Houston, TX | $83,268 | $0 |
| Dr. David Rizzieri, M.d, M.D | Medical Oncology | Charlotte, NC | $79,863 | $0 |
| Michel Velez, Md, MD | Internal Medicine | Orlando, FL | $77,012 | $0 |
| Andrew Seidman, Md, MD | Medical Oncology | New York, NY | $76,198 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $66,207 | $0 |
| Dr. Jeffrey Allerton, Md, MD | Hematology & Oncology | Cooperstown, NY | $66,000 | $0 |
| Chaitali Nangia, Md, MD | Hematology & Oncology | Costa Mesa, CA | $61,030 | $0 |
| Dr. Martin Dietrich, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | Rockledge, FL | $57,827 | $0 |
| Amy Krie, M.d, M.D | Medical Oncology | Minneapolis, MN | $57,405 | $0 |
| Dr. Brittney De Clerck, M.d, M.D | Dermatology | Los Angeles, CA | $56,090 | $0 |
| Hagop Kantarjian, Md, MD | Medical Oncology | Houston, TX | $54,000 | $0 |
About Stemline Therapeutics Inc.
Stemline Therapeutics Inc. has made $23.1M in payments to 7,655 healthcare providers, recorded across 18,533 transactions in the CMS Open Payments database. In 2024, the company paid $4.6M. The top product by payment volume is Orserdu ($6.1M).
Payments were distributed across 128 medical specialties. The top specialty by payment amount is Hematology & Oncology ($1.2M to 1,681 doctors).
Payment categories include: Food & Beverage ($535,218), Consulting ($2.2M), Research ($17.2M), Travel & Lodging ($486,098).
Stemline Therapeutics Inc. is associated with 2 products in the CMS Open Payments database.